scholarly journals Whither Magnetic Hyperthermia? A Tentative Roadmap

Materials ◽  
2021 ◽  
Vol 14 (4) ◽  
pp. 706
Author(s):  
Irene Rubia-Rodríguez ◽  
Antonio Santana-Otero ◽  
Simo Spassov ◽  
Etelka Tombácz ◽  
Christer Johansson ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Nanoparticle Synthesis ◽  
Careful Analysis ◽  
Magnetic Hyperthermia ◽  
Lessons Learned ◽  
In Vivo Testing ◽  
Evolution Of Science ◽  
Made In ◽  
Critical Aspects

The scientific community has made great efforts in advancing magnetic hyperthermia for the last two decades after going through a sizeable research lapse from its establishment. All the progress made in various topics ranging from nanoparticle synthesis to biocompatibilization and in vivo testing have been seeking to push the forefront towards some new clinical trials. As many, they did not go at the expected pace. Today, fruitful international cooperation and the wisdom gain after a careful analysis of the lessons learned from seminal clinical trials allow us to have a future with better guarantees for a more definitive takeoff of this genuine nanotherapy against cancer. Deliberately giving prominence to a number of critical aspects, this opinion review offers a blend of state-of-the-art hints and glimpses into the future of the therapy, considering the expected evolution of science and technology behind magnetic hyperthermia.

scholarly journals A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions

Pathogens ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 426 ◽  
Author(s):  
Sabari Nath Neerukonda ◽  
Upendra Katneni
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Human Population ◽  
Randomized Clinical Trials ◽  
Lessons Learned ◽  
Highly Pathogenic ◽  
In Vivo Models ◽  
Antiviral Therapies

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of CoV disease 2019 (COVID-19) is a highly pathogenic and transmissible CoV that is presently plaguing the global human population and economy. No proven effective antiviral therapy or vaccine currently exists, and supportive care remains to be the cornerstone treatment. Through previous lessons learned from SARS-CoV-1 and MERS-CoV studies, scientific groups worldwide have rapidly expanded the knowledge pertaining to SARS-CoV-2 virology that includes in vitro and in vivo models for testing of antiviral therapies and randomized clinical trials. In the present narrative, we review SARS-CoV-2 virology, clinical features, pathophysiology, and animal models with a specific focus on the antiviral and adjunctive therapies currently being tested or that require testing in animal models and randomized clinical trials.

Experimental Therapeutics

2014 ◽  
Author(s):  
Beth Borowsky ◽  
Cristina Sampaio
Keyword(s):  
Clinical Trials ◽  
Lessons Learned ◽  
Pharmaceutical Companies ◽  
Experimental Therapeutics ◽  
Patient Registries ◽  
Academic Researchers ◽  
History Of ◽  
Insight Into ◽  
Made In

Bringing safe and effective treatments to patients with Huntington’s disease (HD) will require evaluation in properly designed and conducted clinical trials. Such clinical trials will require appropriate tools and practices, including therapeutics, patient registries, biomarkers, endpoints, trial design, and analysis tools. This chapter provides insight into the advances being made in each of these areas and highlights the challenges remaining. Lessons learned from prior HD trials as well as from trials in other neurodegenerative diseases affect our view of future HD clinical development. With much interest from both pharmaceutical companies and academic researchers, this final chapter of the book actually opens a new chapter in the history of HD drug development.

scholarly journals Assessment of Toxicity and Safety Profiles of Nanoparticles

2020 ◽  
Vol 10 (1) ◽  
pp. 1877-1888
Keyword(s):  
Clinical Trials ◽  
Mechanism Of Action ◽  
Safety Assessment ◽  
Nanoparticle Synthesis ◽  
Safety Evaluation ◽  
Drug Molecules ◽  
The World ◽  
Strict Regulation

The world of medicine explored the use of nanoparticles in therapeutics in the last two decades. Owing to the advantages nanoparticles offer, they are proving beneficial to overcome many drawbacks faced by small drug molecules. Since the nature, architecture, shape, size, and mechanism of action of nanomedicines totally different from regularly used drugs, it is important to work on the possible toxicity these nanoparticles are causing so that its safety can be ensured. In today’s scenario, a lot of industries and institutes are synthesizing nano drugs, so it is important to check its toxicity and safety evaluation under in vivo and in vitro conditions, as it has come to fore that number of metal and carbon-based nanoparticles, although proving useful further display increased toxicity. Taken into consideration nanoparticle toxicity and safety, the present review discusses the exact working of nanoparticles at the molecular, cellular, and physiological levels and the toxicity associated with it. The present strategies for safety assessment have also been reviewed. The research involving nanomaterials in therapeutics demand strict regulation in nanoparticle synthesis, its usage, properly regulated clinical trials ensuring safety assessment.

scholarly journals A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models and Anti-Viral Interventions

2020 ◽  
Author(s):  
Sabarinath Neerukonda ◽  
Upendra Katneni
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Randomized Clinical Trials ◽  
Lessons Learned ◽  
Highly Pathogenic ◽  
In Vivo Models ◽  
Viral Therapy ◽  
Anti Viral Therapy

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of CoV disease 2019 (COVID-19) is a highly pathogenic and transmissible CoV that is presently plaguing the global human population and economy. No proven effective anti-viral therapy or vaccine currently exist, and supportive care remains to be the cornerstone treatment. Through previous lessons learned from SARS-CoV-1 and MERS-CoV studies, scientific groups worldwide have rapidly expanded the knowledge pertaining to SARS-CoV-2 virology that included in vitro and in vivo models for testing of anti-viral therapies, and randomized clinical trials. In the present narrative, we review SARS-CoV-2 virology, clinical features, pathophysiology, and animal models with a specific focus on anti-viral and adjunctive therapies currently being tested or require testing in animal models and randomized clinical trials.

Synthesis, Properties, and in vivo Testing of Biogenic Ferrihydrite Nanoparticles

2020 ◽  
Vol 84 (11) ◽  
pp. 1366-1369
Author(s):  
S. V. Stolyar ◽  
V. P. Ladygina ◽  
A. V. Boldyreva ◽  
O. A. Kolenchukova ◽  
A. M. Vorotynov ◽  
...  
Keyword(s):  
Synthesis Properties ◽  
In Vivo Testing

Modulation of Matrix Metalloproteinases by Plant-Derived Products

2020 ◽  
Vol 20 ◽  
Author(s):  
Nur Najmi Mohamad Anuar ◽  
Nurul Iman Natasya Zulkafali ◽  
Azizah Ugusman
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Matrix Metalloproteinases ◽  
Animal Studies ◽  
Current Knowledge ◽  
In Vitro Models ◽  
In Vivo Studies ◽  
Extracellular Matrix Components

: Matrix metalloproteinases (MMPs) are a group of zinc-dependent metallo-endopeptidase that are responsible towards the degradation, repair and remodelling of extracellular matrix components. MMPs play an important role in maintaining a normal physiological function and preventing diseases such as cancer and cardiovascular diseases. Natural products derived from plants have been used as traditional medicine for centuries. Its active compounds, such as catechin, resveratrol and quercetin, are suggested to play an important role as MMPs inhibitors, thereby opening new insights into their applications in many fields, such as pharmaceutical, cosmetic and food industries. This review summarises the current knowledge on plant-derived natural products with MMP-modulating activities. Most of the reviewed plant-derived products exhibit an inhibitory activity on MMPs. Amongst MMPs, MMP-2 and MMP-9 are the most studied. The expression of MMPs is inhibited through respective signalling pathways, such as MAPK, NF-κB and PI3 kinase pathways, which contribute to the reduction in cancer cell behaviours, such as proliferation and migration. Most studies have employed in vitro models, but a limited number of animal studies and clinical trials have been conducted. Even though plant-derived products show promising results in modulating MMPs, more in vivo studies and clinical trials are needed to support their therapeutic applications in the future.

Pharmacology of 5-HT1A Receptors: Critical Aspects

CNS Spectrums ◽  
1998 ◽  
Vol 3 (10) ◽  
pp. 17-38 ◽  
Author(s):  
Franco Borsini
Keyword(s):  
Receptor Subtypes ◽  
Laboratory Conditions ◽  
In Vivo Effects ◽  
Critical Aspects

AbstractMyriad difficulties exist in analyzing the pharmacology of the serotonin 1A (5-HT1A) receptor. The receptor may demonstrate a different activity depending on the tissue or species used for analysis, the agent used, laboratory conditions, and differences between in vitro and in vivo effects of compounds. Affinity for 5-HT receptors also varies widely, presenting difficulties in drawing definitive conclusions on affinity values for various compounds. At least two possibilities exist to explain the diversity of pharmacology of 5-HT receptors. First, it is possible that different 5-HT1A receptor subtypes exist. Second, the 5-HT1A receptors may play a far more complex role than previously believed.

scholarly journals H3ABioNet genomic medicine and microbiome data portals hackathon proceedings

Database ◽  
2021 ◽  
Vol 2021 ◽  
Author(s):  
Faisal M Fadlelmola ◽  
Kais Ghedira ◽  
Yosr Hamdi ◽  
Mariem Hanachi ◽  
Fouzia Radouani ◽  
...  
Keyword(s):  
Ethnic Groups ◽  
Genomic Medicine ◽  
Lessons Learned ◽  
Team Work ◽  
Significant Progress ◽  
Team Members ◽  
Pan African ◽  
Scientific Expertise ◽  
Microbiome Data ◽  
Made In

Abstract African genomic medicine and microbiome datasets are usually not well characterized in terms of their origin, making it difficult to find and extract data for specific African ethnic groups or even countries. The Pan-African H3Africa Bioinformatics Network (H3ABioNet) recognized the need for developing data portals for African genomic medicine and African microbiomes to address this and ran a hackathon to initiate their development. The two portals were designed and significant progress was made in their development during the hackathon. All the participants worked in a very synergistic and collaborative atmosphere in order to achieve the hackathon's goals. The participants were divided into content and technical teams and worked over a period of 6 days. In response to one of the survey questions of what the participants liked the most during the hackathon, 55% of the hackathon participants highlighted the familial and friendly atmosphere, the team work and the diversity of team members and their expertise. This paper describes the preparations for the portals hackathon and the interaction between the participants and reflects upon the lessons learned about its impact on successfully developing the two data portals as well as building scientific expertise of younger African researchers. Database URL: The code for developing the two portals was made publicly available in GitHub repositories: [https://github.com/codemeleon/Database; https://github.com/codemeleon/AfricanMicrobiomePortal].

Sign in / Sign up

Export Citation Format

Share Document